Posted by Michael Wonder on 09 Nov 2020
Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia
9 November 2020 - Calquence demonstrated superior progression-free survival and favourable tolerability in both previously untreated and relapsed or refractory patients
AstraZeneca’s Calquence (acalabrutinib), a next-generation selective Bruton’s tyrosine kinase inhibitor, has been approved in the European Union for the treatment of adult patients with chronic lymphocytic leukaemia, the most common type of leukaemia in adults.
